"FDA halts uniQure’s plans for Huntington’s disease gene therapy" was originally created and published by Pharmaceutical ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now unclear." ...

MRI of a brain with Huntington's Disease. Every week neurologist Victor Sung sees people with Huntington’s disease, a rare and devastating neurodegenerative disorder, at his clinic at the University ...

The post FDA Feedback Surprises Huntington’s Drug Watchers appeared first on Self Employed.

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.

Nearly 150 people gathered at Waterfront Park on Sunday for the Huntington’s Disease Society of America’s Team Hope Walk, uniting families, advocates and supporters. IMPORTANCE. ACCORDING TO THE ...

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...

October was an insight-rich month in Huntington’s disease research: additional clarity around uniQure’s AMT-130, mapping how and where HD changes the brain, early mechanistic studies targeting DNA ...

Huntington’s disease (HD) develops when people have a repetition of the genetic letters C-A-G in their huntingtin gene. People with 40 or more repeats will develop the disease during their lifetime, ...